(UroToday.com) The 2023 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. William Kelly discussing interim results from a phase 1 study of AMG 509 (xaluritamig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results